PLANTATION, FL / ACCESSWIRE / December 16, 2019 / LMP Automotive Holdings, Inc. (NASDAQ:LMPX) (the "Company" "LMP"), an e-commerce and facilities-based platform for consumers who desire to buy, sell, rent, subscribe for or finance pre-owned and new automobiles, today announced the hiring of Stuart Jamieson as Director of Acquisitions.

"On behalf of LMP, I would like to welcome Stuart to the team" said Sam Tawfik, the Company's Chairman and Chief Executive Officer, adding that this is an important step for the Company, because in 2020, LMP intends to become a sophisticated and aggressive, technology-fluent and online-centric, franchise dealership acquirer, targeting dealership groups in the Northeast, Southeast and the Mid-West. Mr. Jamieson has agreed to start immediately, given the influx of acquisition opportunities to review.

Mr. Tawfik went on to say, "Stuart has a multitude of disciplines including over 30 years of extensive knowledge and experience in capital markets, financial analysis and operations. He has managed all aspects of over 75 acquisitions and transactions valued in excess of $6.5 billion within the Consumer, Automotive, Technology, Industrial Products, and Aerospace industries and will immediately be charged with managing and expediting the current and future deal flow from review through the execution of acquisition agreements."

Mr. Jamieson stated, "I am excited and honored to work with Mr. Tawfik and the LMP team with their award winning track record of successes."

Over the last twenty years, Mr. Jamieson has served as Managing Director and Board of Directors member of numerous private equity companies specializing in the acquisition, growth, turnaround, and consolidations of middle-market companies. His specific transactional skills include target identification and valuation, financial and legal due diligence, preparation of LOI's, stock and asset purchase agreements, transaction structuring and negotiation, as well as financing the transactions with both debt and equity. His post-acquisition responsibilities include financial and operational hands-on executive management as CEO, President, and CFO, evaluation of add-on acquisitions, divestitures, strategic planning, financing, and growth and exit strategies for portfolio companies. He has served on the Board of Directors and acted as Chairman on numerous portfolio companies.

Earlier in his career, Mr. Jamieson has over 10 years of financial, operational, turnaround, and special project experience, both domestic and in 10 international countries, with companies such as United Technologies, Litton Industries, AIG and the Singer Company. Earlier in his career, he focused primarily on corporate acquisitions and restructurings, M&A, re-engineering, forensic accounting, litigation support, cash management and internal and financial auditing. He began his career with the public accounting firm of Ernst & Young where he earned his CPA. Mr. Jamieson received his Bachelor of Business Administration in Accounting and Finance from Bryant University.

About LMP Automotive Holdings, Inc. – "Buy, Rent or Subscribe, Sell and Repeat."

LMP Automotive Holdings, Inc. (NASDAQ: LMPX) describes its business model as "Buy, Rent or Subscribe, Sell and Repeat." This means that we "Buy" pre-owned automobiles primarily through auctions or directly from other automobile dealers, and new automobiles from manufacturers and manufacturer distributors at fleet rates. We "Rent or Subscribe" by either renting automobiles to our customers or allowing them to enter into our subscription plan for automobiles in which customers have use of an automobile for a minimum of thirty (30) days. LMP's all-inclusive vehicle subscription membership includes monthly swaps and covers insurance, maintenance and upkeep. It offers the flexibility to upgrade your vehicle to a more premium model or downgrade for a lesser cost model when you like. We "Sell" our inventory, including automobiles previously included in our rental and subscription programs, to customers as well, and then we "Repeat" the whole process.

Media Contact:

John Mattio
President and Founder
Lamnia International
(203) 885-1058
jmattio@lamniacom.com

For more information visit: https://lmpmotors.com/.

FORWARD-LOOKING STATEMENTS:

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar matters that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: our dependence upon external sources for the financing of our operations; our ability to effectively executive our business plan; our ability to maintain and grow our reputation and to achieve and maintain the market acceptance of our services and platform; our ability to manage the growth of our operations over time; our ability to maintain adequate protection of our intellectual property and to avoid violation of the intellectual property rights of others; our ability to maintain relationships with existing customers and automobile suppliers, and develop relationships; and our ability to compete and succeed in a highly competitive and evolving industry; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

SOURCE: LMP Automotive Holdings, Inc.

ReleaseID: 570353

VANCOUVER, BC / ACCESSWIRE / December 16, 2019 / Alchemist Mining Inc. (CSE:AMS) ("AMS" or the "Company") is pleased to provide an update on the progress of its corporate initiatives and financing.

Dear shareholders, 2019 has been a challenging year for the entire cannabis sector. Company valuations have plummeted, and many in our industry have shut their doors and turned out their lights. In a market where financing has dried up, and stock prices have crashed, the team at AMS is still working hard to ensure that we succeed in executing our business plan. Despite the dire market conditions, our internal challenges, and the current industry outlook, we have continued our forward (albeit at a snail's pace) motion. Many of our shareholders have reached out to us in recent months with questions related to the company's current position, its short-term and long-term plan, and of course, the constant question, when will the company resume trading.

We are working diligently to secure the financing needed to start trading again, but market conditions have seen many investment brokers, bankers, and independent investors step to one side, adopting a very cautionary approach to their Cannabis portfolios. In recent months we have presented to more than 25 investment groups, almost all of whom have taken the approach that it's better to wait it out on the sidelines than to invest now. Therefore, we have started to focus on securing private equity, convertible debentures, and even straight debt. However, we have yet to secure a minimum of $3.5 million dollars needed to start trading again. Our management and staff have committed themselves to the success of the company, so much so, that none of us have taken any salaries since July of this year, preserving what little funds we have for critical expenditures only.

In the short term, while we continue to look for the right investment partners, we are concentrating on generating enough revenue to support the company's operations. To this end, we have launched a "light" version of Oddysee and are working closely with Green Rush Consulting to roll it out throughout the United States. We are also focused on developing sales and distribution channels for our CBD products, specifically transdermal patches and pain creams. This strategy is proving successful with sales already secured in Canada and the USA and pricing proposals submitted to the EU and regions of Asia and the Middle East.

As we near the end of the year I want personally thank all those who have reached out to us and offered their support and well wishes, I also want to assure you all that the staff, management, and board of directors at Alchemist are working diligently to ensure the success of our company and the ultimate increase in its shareholder value.

Sincerely,

Paul Mann
President & CEO
Alchemist Mining Inc.

For further information on this release, please contact:

Sukh Sandhu Investor Relations
Investors@alchemistinc.ca
1-844-420-2254 ext 401

About Alchemist Mining Inc.

Upon effecting the Company's fundamental change, as announced on September 25, 2018, Alchemist's goal is to be a global provider of technology solutions to the cannabis sector. It will be primarily focused on investing and building a sustainable portfolio of business entities, by actively identifying opportunities in the developing global cannabis market, through a combination of acquisitions, incubations and investments, with a goal to create shareholder value.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "intends", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties, including: that the Company will not be able to execute its proposed business plan in the time required or at all due to regulatory, financial or other issues; that the Company's competitors may develop competing technologies; changes in regulatory requirements; and other factors beyond the Company's control. Additional risk factors are included in the Company's Management's Discussion and Analysis, available under the Company's profile on www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where because of new information, future events or results, or otherwise, except as required by applicable securities laws.

SOURCE: Alchemist Mining Inc.

ReleaseID: 570334

CHARLOTTESVILLE, VA / ACCESSWIRE / December 16, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received a Notice of Allowance for the issuance of a patent by the United States Patent and Trademark Office (USPTO), titled: "Serotonin Transporter Gene and Treatment of Alcoholism." This patent addresses a method of treating alcohol use disorder (AUD) in patients with a specific genetic biomarker in the serotonin transporter gene by administering the Company's investigational new drug product, AD04, a 5-HT3 antagonist, to patients with the TT genotype. This patent builds upon a previous Company patent for patients with the LL/TT genotype.

The genetic biomarker is part of the genetic panel used to identify patients expected to respond to treatment with AD04. As previously announced, Adial recently completed the validation of its proprietary genetic test through its partnership with Eurofins Biopharma Services. This test will be used to identify potential subjects for inclusion in the planned Phase 3 trial of AD04 as a treatment for AUD in biomarker positive subjects.

William Stilley, Chief Executive Officer of Adial Pharmaceuticals, commented, "We continue to aggressively build our patent estate around AD04. This is the second Notice of Allowance by the USPTO in the same patent family targeting patients with specific biomarkers in the serotonin transporter gene. This marks another important milestone as we progress towards commencing our Phase 3 trial of AD04. By targeting specific genotypes, we believe that we have uniquely positioned AD04 as a potential best-in-class therapy for the treatment of alcohol use disorder, and our patent strategy is to develop the broadest patent protection possible by filing multiple patents within the same patent domain to make it more difficult for potential future competitors."

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug product, AD04, is a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD). A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. AD04 is also believed to have the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity. www.adialpharma.com

Forward Looking Statements

This communication contains certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could" are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding the use of the test to identify potential subjects for inclusion in the planned Phase 3 trial of AD04 as a treatment for AUD in biomarker positive subjects, the targeting of specific genotypes, uniquely positioning AD04 as a potential best-in-class therapy for the treatment of alcohol use disorder and the potential of AD04 to treat AUD and other addictive disorders such as opioid use disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to commence the Phase 3 clinical trials as expected, the ability to expand the use of AD04 for use in patients with opioid use disorder, gambling and obesity, the ability of AD04 therapy to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, our ability to maintain our license agreements, our ability to implement our patent strategy and continue the maintenance and growth of our patent estate, our ability to establish and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund its research and development activities, and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2018, subsequent Quarterly Reports on Form 10-Q and Current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.

Contact:

Crescendo Communications, LLC
David Waldman / Natalya Rudman
Tel: 212-671-1021
Email: dwaldman@crescendo-ir.com

SOURCE: Adial Pharmaceutical, Inc.

ReleaseID: 570351

INCLINE VILLAGE, NV / ACCESSWIRE / December 16, 2019 / American Battery Metals Corporation (OTCQB:ABML) (the "Company"), a premier battery metal exploration and development and battery recycling company based in Nevada, spent another week in Washington, D.C. to discuss U.S. economic and national security issues and battery metals independence.

Representatives from American Battery Metals Corporation included Chief Executive Officer Doug Cole, Chief Technical Officer Ryan Melsert, and Head of Business Development and Government Affairs, Doug Nickle. While the team met with both Democrat and Republican lawmakers at a time of intense political gridlock in the nation's capital, American Battery Metals Corporation was well received as the company articulated its strategy to help the United States lessen its reliance on foreign sources of critical minerals.

"Regardless of what else is happening in D.C., energy independence and renewable resources are top of mind for our elected and appointed officials," said Doug Cole. Cole continued, "As American Battery Metals Corporation shares our plans to bring new primary resources of critical minerals like lithium online, lawmakers and other officials are also keenly interested in our e-waste solution for battery recycling, which has the double benefit of returning the acutely-needed battery metals from end of life cells and scrap materials back into the supply chain."

American Battery Metals Corporation met with key support staff of the House and Senate committees, including the House Committee on Natural Resources, Subcommittee on Energy and Mineral Resources and the Senate Energy and Natural Resources Committee. Officials from the Department of Energy, Office of Energy Efficiency and Renewable Energy, Vehicle Technologies Office welcomed American Battery Metals Corporation to further discuss the company's lithium-ion battery recycling solution that recovers each of the metals from a rechargeable battery, including lithium, cobalt, nickel, copper, aluminum, and manganese.

"United States officials are well aware of the imperative that America must become a global player in battery metals production," said Doug Nickle. "The lawmakers, staff, and officials we met with are actively working with the private sector to find the best path forward for the US to become a leader in the ethical production and recycling of the battery metals that will fuel the electric revolution."

American Battery Metals is unique in many ways. The company is fully integrated, executing its strategies in exploration and mining, extraction, and battery recycling. Beyond providing solutions to supply chain challenges that affect US national and economic security, American Battery Metals Corporation is a leader in advocating for environmentally-sustainable practices. American Battery Metals Corporation is pioneering bold, innovative technologies across its verticals. "Doing well by doing good is not a catchphrase for American Battery Metals Corporation," said Nickle. "We believe we have an obligation to lead the way when it comes to next-gen practices that don't negatively offset the green benefits of the global move toward electrification."

American Battery Metals Corporation

American Battery Metals Corporation (www.batterymetals.com) (OTCQB:ABML) is a premier battery metal exploration and development company based in Nevada. The company is focused on its Railroad Valley battery metal project in Nevada with the goal of becoming a substantial domestic supplier of battery metals to the increasing electric vehicles and battery storage markets in America.

For more information, please visit:www.batterymetals.com

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including those with respect to the expected project economics for Western Nevada Basin (Railroad Valley), including estimates of life of mine, average production, cash costs, AISC, initial CAPEX, sustaining CAPEX, pre-tax IRR, pre-tax NPV, net cash flows and recovery rates, the impact of self-mining versus contract mining, the timing to obtain necessary permits, the submission of the project for final investment approval and the timing of initial gold production after investment approval and full financing, metallurgy and processing expectations, the mineral resource estimate, expectations regarding the ability to expand the mineral resource through future drilling, ongoing work to be conducted at the Western Nevada Basin (Railroad Valley), and the potential results of such efforts, the potential commissioning of a Pre-Feasibility study and the effects on timing of the project, are "forward-looking statements." Although the Company's management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward-looking statements involve a number of risks and uncertainties, which could cause the Company's future results to differ materially from those anticipated. Potential risks and uncertainties include, among others, interpretations or reinterpretations of geologic information, unfavorable exploration results, inability to obtain permits required for future exploration, development or production, general economic conditions and conditions affecting the industries in which the Company operates; the uncertainty of regulatory requirements and approvals; fluctuating mineral and commodity prices, final investment approval and the ability to obtain necessary financing on acceptable terms or at all. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended September 30, 2018. The Company assumes no obligation to update any of the information contained or referenced in this press release.

Contact Information

p775-473-4744
info@batterymetals.com

SOURCE: American Battery Metals Corp.

ReleaseID: 570285

Signing Up Affiliate Marketers, Distributors and Customers

MIAMI, FL / ACCESSWIRE / December 16, 2019 / GH Capital, Inc. (OTC PINK:GHHC), through its Vitana-X sunsidiary, a provider of comprehensive programs for greater well-being, fitness and health with a wellness network marketing program, is pleased to announce that it has successfully completed a 7-city tour across Europe. The roadshow was led by Vitana-X's Chief Operating Officer Matthias Goeth.

The purpose of the tour was to create awareness and business leads for its multi-level marketing programs centered around well-being, fitness and health, including its REVIVAL lifestyle drink. The exclusively invited audiences were in the most strategic cities across Austria and Switzerland, and included experts from the fields of health, research, sports and business.

The Vitana-X team is looking to engage with and sign up affiliate marketers, distributors and customers, in anticipation of its full launch in early 2020.

Another multi-city tour will start by the end of December, and will include important cities in Germany and Hungary, in addition to Austria and Switzerland.

About GH Capital / Vitana-X

GH Capital, Inc.'s (OTC: GHHC) Vitana-X, an international wellness company specializing in the development and manufacture of health-promoting products based on DNA analysis. As a pioneer in this industry and a worldwide network of highly qualified experts, it offers its customers extensive opportunities to lead a healthier life. Vitana-X offers comprehensive programs for greater well-being, fitness and health by helping you achieve the desired results and offering exercises that fit your body type. Vitana-X wants to support people in their healthy development and be their reliable partner for their full potential. Vitana-X comes from two worlds and wants to unite them in the future – science and the challenges of daily life, so that its customers can continue to care for other areas of life without sacrificing a healthy life.

For additional information on Vitana-X, please visit: http://vitana-x.net.

Forward-Looking Statements

Forward-Looking Statements. This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words "believe," "anticipate," "estimate," "expect," "intend," "plan," "project," "prospects," "outlook," and similar words or expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could" are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Form 10-K filed on December 28, 2018, for the fiscal year ended September 30, 2018, including but not limited to the discussion under "Risk Factors" therein, which the Company has filed with the SEC and which may be viewed at http://www.sec.gov.

Contact Information

press@ghcapital-inc.us
305-714-9397

SOURCE: GH Capital, Inc.

ReleaseID: 570348

DENVER, CO / ACCESSWIRE / December 16, 2019 / Solitario Zinc Corp. ("Solitario") (NYSE American:XPL)(TSX:SLR) is pleased to provide the remaining drill results from its 2019 drilling program on its Florida Canyon zinc project in Peru. Florida Canyon is joint ventured with, and operated by the world's fourth largest zinc miner, Nexa Resources S.A. (NEXA) ("Nexa").

Highlights of the drill results reported in this release include the following significant intercepts of zinc equivalent ("ZnEq") mineralization.

Drill Hole PEBGD000036: 6.1 meters grading 26% ZnEq
Drill Hole PEBGD000038: 9.7 meters grading 23% ZnEq
Drill Hole PEBGD000039: 3.3 meters grading 47% ZnEq

Previously unreported drill holes PEBGD000034 through 39 expanded three different high priority targets. The San Jorge zone, and two newly emerging zones: the 1021 and the manto-hosted mineralization east of San Jorge. All five of the drill holes that successfully reached their target, intersected significant mineralization which should contribute to expanding the Florida Canyon resource base. The sixth hole was lost due to drilling problems.

Hole PEBGD000036 cut four intervals of high-grade zinc (including 6.1 m of 26% ZnEq) extending the 1021 Zone approximately 53 meters north of the previously reported 2019 drill hole PEBGD000033 that contained 9.9 meters grading 7.7% ZnEq. A long section of the 1021 Zone, can be seen here.

Hole PEBGD000038 (9.7m, 23% ZnEq) offset, updip and to the south, the previously reported hole PEBGD000015 (12.4m at 15.1% ZnEq) in the expanding southern extension of the San Jorge Zone.

Drill hole PEBGD000039 defined two horizontal manto zones: 3.3 meters grading 47.1% and 4.3 meters of 6.6% ZnEq to the east of the San Jorge vertical replacement body. This hole correlates well with previously reported drill hole PEBGD000032 that intersected 9.3 meters of 26.5% and 3.1 meters of 19.7% ZnEq approximately 70 meters to the north.

The full results for the final drill holes for the 2019 drilling program are reported below. Please see prior news releases for previously reported drilling results from the 2019 drilling program at Florida Canyon.

Highlights of Florida Canyon Drilling Results

Drill Hole

From

To

Interval

Zinc

Lead

Silver

Zinc-Eq*

Number

(m)

(m)

(m)

(%)

(%)

(g/t)

(%)

PEBGD000034

440.9

443.7

2.8

7.0

0.0

9.8

7.2

491.9

492.9

1.0

31.7

0.0

36.5

32.5

PEBGD000035

Hole Lost due to Drilling Problems

PEBGD000036

287.2

293.3

6.1

20.1

5.6

42.4

25.6

301.0

302.5

1.5

13.7

1.0

24.2

15.0

307.8

309.6

1.8

35.2

0.5

69.7

37.1

362.0

364.6

1.7

2.8

8.3

24.9

11.2

PEBGD000037

305.4

306.4

1.0

14.5

5.2

25.2

19.3

PEBGD000038

423.3

433.0

9.7

22.8

0.2

11.8

23.2

PEBGD000039

328.8

332.1

3.3

37.7

9.6

65.5

47.1

447.0

451.3

4.3

6.4

0.2

2.2

6.6

*Zn-Eq was calculated using the following price assumptions: Zn=$1.10/lb., Pb=$0.91lb., Ag=$16.50/oz.
Reported intervals are estimated to be at least 80% of the true thickness
Numbers in this table may not add exactly as numbers have been rounded to the nearest decimal

Chris Herald, President and Chief Executive Officer of Solitario, commented:

"The final results of the 2019 Florida Canyon drilling program were exceptional and topped off a very successful 2019 drilling program. Nexa and Solitario achieved our three most important objectives: 1) expanding the near-vertical San Jorge body to the south and its associated high-grade horizontal mantos to the east; 2) discovering and partially defining the 1021 Zone over a minimum strike length of 800 meters; and, 3) extending a number of horizontal mantos in the Karen-Milagros area. Great potential still exists to significantly expand the Florida Canyon mineralized system, particularly to the south where several strong surface prospects were discovered in 2018 demonstrating a corridor four kilometers long that is totally untested by drilling."

Drill hole information contained within this release is reported under Nexa's quality control program reviewed by Mr. Walt Hunt, COO for Solitario Zinc Corp., who is a qualified person as defined by National Instrument 43-101. Samples are derived from 50% splits of HQ and NQ (2.5 and 1.9 inch) diameter core. Samples are shipped via secured third-party land transportation companies and analyzed by ALS Global Inc., in Lima, Peru.

Terms of the Florida Canyon Joint Venture

Solitario owns a 39% interest and Nexa owns a 61% indirect interest in the Florida Canyon project. Nexa can earn a 70% interest in the Florida Canyon project by continuing to fund all project expenditures and committing to place the project into production based upon a positive feasibility study. After earning 70%, and at the request of Solitario, Nexa has further agreed to finance Solitario's 30% participating interest for construction through a project loan. Solitario will repay the loan facility through 50% of its net cash flow distributions from production.

About Solitario

Solitario is an emerging zinc exploration and development company traded on the NYSE American ("XPL") and on the Toronto Stock Exchange ("SLR"). Solitario holds 50% joint venture interest in the high-grade, open-pittable Lik zinc deposit in Alaska and a 39% joint venture interest (Nexa Resources holds the remaining 61% interest) on the high-grade Florida Canyon zinc project in Peru. Solitario also holds a 9.9% equity interest in Vendetta Mining. Solitario's Management and Directors hold approximately 9.3% (excluding options) of the Company's 58.1 million shares outstanding. Solitario's cash balance and marketable securities stand at approximately US$8.8 million. Additional information about Solitario is available online at www.solitariozinc.com

FOR MORE INFORMATION ABOUT SOLITARIO, CONTACT:

Valerie Kimball
Director – Investor Relations
(720) 933-1150
(800) 229-6827

Christopher E. Herald
President & CEO
(303) 534-1030, Ext. 14

Cautionary Statement Regarding Forward Looking Information

This press release contains forward-looking statements within the meaning of the U.S. Securities Act of 1933 and the U.S. Securities Exchange Act of 1934, and as defined in the United States Private Securities Litigation Reform Act of 1995 (and the equivalent under Canadian securities laws), that are intended to be covered by the safe harbor created by such sections. Forward-looking statements are statements that are not historical fact. They are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made and address activities, events or developments that Solitario expects or anticipates will or may occur in the future, and are based on current expectations and assumptions. Forward-looking statements involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Such forward-looking statements include, without limitation, statements regarding the Company's expectation of the projected timing and outcome of engineering studies; expectations regarding the receipt of all necessary permits and approvals to implement a mining plan, if any, at Lik or Florida Canyon; the potential for confirming, upgrading and expanding zinc, lead and silver mineralized material; future operating and capital cost estimates may indicate that the stated resources may not be economic; estimates of zinc, lead and silver grades of resources provided are predicted and actual mining grade could be substantially lower; estimates of recovery rates for could be lower than estimated for establishing the cutoff grade; and other statements that are not historical facts could vary significantly from assumptions made in the PEA. Although Solitario management believes that its expectations are based on reasonable assumptions, it can give no assurance that these expectations will prove correct. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, among others, risks relating to risks that Solitario's and its joint venture partners' exploration and property advancement efforts will not be successful; risks relating to fluctuations in the price of zinc, lead and silver; the inherently hazardous nature of mining-related activities; uncertainties concerning reserve and resource estimates; availability of outside contractors, and other activities; uncertainties relating to obtaining approvals and permits from governmental regulatory authorities; the possibility that environmental laws and regulations will change over time and become even more restrictive; and availability and timing of capital for financing the Company's exploration and development activities, including uncertainty of being able to raise capital on favorable terms or at all; as well as those factors discussed in Solitario's filings with the U.S. Securities and Exchange Commission (the "SEC") including Solitario's latest Annual Report on Form 10-K and its other SEC filings (and Canadian filings) including, without limitation, its latest Quarterly Report on Form 10-Q. The Company does not intend to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.

SOURCE: Solitario Zinc Corp.

ReleaseID: 570186

REDWOOD, CA / ACCESSWIRE / December 16, 2019 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), is pleased to announce that Tamara Elias, MD, has been appointed to the Company's Board of Directors, effective December 12, 2019. Dr. Elias has been actively involved with healthcare for more than 20 years in strategic consulting, private equity investing, corporate strategy, business development and product innovation.

Dr. Elias most recently served as Vice President of Clinical Product Development at Aetna, focused on optimizing and rationalizing the clinical product portfolio for all lines of business as well as aligning future product and service design with the Aetna digital roadmap and customer needs within each business segment. From 2015 to 2017, Dr. Elias was Vice President of Corporate Strategy and Business Development for the $8 billion medical segment at Becton Dickinson and was a member of the leadership team involved in the $24 billion acquisition of C.R. Bard.

From 2007-2015, Dr. Elias was a Partner with Essex Woodlands Healthcare Partners, a healthcare only growth equity firm founded in 1985 and currently with over $3 billion in funds raised to date. There she focused on medical device, healthcare services and healthcare IT investments and served on several boards, including Millennium Pharmacy Systems (sold to Pharmerica), BreatheAmerica, Influence Health (sold to Healthgrades) and ATS Medical (sold to Medtronic). Earlier in her career, Dr. Elias was a management consultant at McKinsey, advising pharmaceutical, diagnostic and device companies in R&D, product commercialization and M&A.

Dr. Elias holds degrees in Biology and Anthropology from Yale University, and an M.D. from The Johns Hopkins School of Medicine. She trained as a general surgeon at Massachusetts General Hospital.

"We are thrilled to have Dr. Elias join our Board, bringing the benefit of her expertise as a clinician and surgeon as well as extensive work in corporate strategy and the medical technology marketplace," said Jeff Soinski, Avinger's President and CEO. "Her experience at world class organizations like McKinsey, Becton Dickinson, Essex Woodlands, and Aetna will provide valuable perspective as we continue to expand our clinical network, bring additional devices to market and drive operating efficiencies through the growth of our commercial business."

"I look forward to working with the team at Avinger to advance the company's mission of radically improving the way vascular disease is treated," said Dr. Elias. "With a highly differentiated technology platform, growing product portfolio and emphasis on market expansion, I believe the company can make important contributions to improving the standard of care for patients with PAD, while building a compelling business."

About Avinger, Inc.

Avinger is a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system for the diagnosis and treatment of patients with peripheral artery disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million people worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include the risks described in the section entitled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 6, 2019, as well as in our Quarterly Reports on Form 10-Q. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Avinger disclaims any obligation to update these forward-looking statements.

Public Relations Contact:

Phil Preuss
VP of Marketing & Business Operations
Avinger, Inc.
(650) 241-7942
pr@avinger.com

Investor Contact:

Mark Weinswig
Chief Financial Officer
Avinger, Inc.
(650) 241-7916
ir@avinger.com

Matt Kreps
Darrow Associates Investor Relations
(214) 597-8200
mkreps@darrowir.com

SOURCE: Avinger, Inc.

ReleaseID: 570284

SAN FRANCISCO, CA / ACCESSWIRE / December 16, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that a clinical research study initiated and sponsored by The University of Texas Health Science Center at Houston (UTHealth) will be supported by Jaguar's wholly-owned subsidiary, Napo Pharmaceuticals, Inc. ("Napo"). The study will evaluate the safety and effectiveness of crofelemer for treatment of chronic idiopathic diarrhea in patients (the "Study"). The Study is expected to begin enrolling patients in the fourth quarter of 2019. Crofelemer (Mytesi®) is the Company's FDA-approved orally administered botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest.

Chronic idiopathic diarrhea is a common complaint of patients presenting to family practitioners and internists, and is one of the most common reasons for referral to gastroenterologists. It is estimated that the prevalence of chronic idiopathic diarrhea in developed countries (including the U.S.) is approximately 3-5%. It has a significant negative effect on health-related quality of life and causes a high economic burden on patients and society. The American Gastroenterological Association Burden of Illness study (2012) showed that the estimated annual direct and indirect costs associated with chronic idiopathic diarrhea is up to $524 million per year and $136 million per year, respectively.

The primary objective of the Study will be to evaluate the safety and efficacy of crofelemer in patients with chronic idiopathic diarrhea. Adult patients with a diagnosis of noninfectious chronic idiopathic diarrhea (defined as >20 bowel movements per week of which >50% are watery bowel movements) will be included in the Study. Subjects will receive crofelemer (Mytesi) 125 mg delayed-release tablets twice daily, with or without food for four weeks. Reduction in weekly stool frequency as well as changes in stool consistency and quality of life improvements will be evaluated at the end of the Study.

The principal investigator for the Study will be Dr. Brooks D. Cash, MD, AGAF, FACG, FACP, FASGE, Chief – Division of Gastroenterology, Hepatology and Nutrition, Sterling Professor of Medicine, McGovern Medical School at UTHealth, Co-Director, Ertan Digestive Disease Center at Memorial Hermann-Texas Medical Center. The Study is titled Yield of Diagnostic Tests and Management of Crofelemer for Chronic Idiopathic Diarrhea in Non-HIV Patients: A Pilot Study, and is a single-center trial at UTHealth.

About Jaguar Health, Inc.

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.

For more information about Jaguar, please visit jaguar.health. For more information about Napo, visit napopharma.com.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

ReleaseID: 570252

CALGARY, AB / ACCESSWIRE / December 16, 2019 / CANEX Metals Inc. (TSXV:CANX) ("CANEX" or the "Company") is pleased to announce assay results for 14 rock samples from the Pit Zone at the Company's Gold Range Property in Arizona.

In October the Company collected 14 grab and chip samples from the Pit Zone as part of a property wide prospecting and mapping program. All of the samples from the Pit Zone have returned high grade gold, highlighted by 11 grab samples over a 500 metre by 70 metre area that have returned between 8.8 and 48.1 g/t gold, averaging 25.5 g/t gold. In addition, a 0.5 metre chip sample returned 26.7 g/t gold, and chip samples across the northern face of the open pit have returned 2.3 g/t Au over 8 metres, with the zone remaining open in all directions. Photographs of the Pit Zone and select sample locations are available here.

Samples from the Pit Zone – Gold Range Property

Sample

Zone

Type*

Au g/t

Ag g/t

Cu %

547169

Pit

Grab

38.3

15.7

0.28

547170

Pit

Grab

31.9

8.5

0.17

547171

Pit

Grab

30.1

14.8

0.39

547172

Pit

Grab

21.9

4.9

0.65

547177

Pit

3.5m Chip

2.53

0.7

0.01

547178

Pit

4.5m Chip

2.19

6.1

0.02

177 & 178

Pit

8m Chip

2.34

3.7

0.02

547179

Pit

Grab

48.1

10.4

0.59

547180

Pit

grab

23.5

3.5

0.14

547181

Pit

grab

8.87

0.9

0.01

547182

Pit

Composite Grab

8.8

1.8

0.01

547183

Pit

Grab

14.5

3.1

–

547184

Pit

Grab

25.3

6.7

0.12

547185

Pit

Grab

29.3

4.8

0.01

547186

Pit

0.5m Chip

26.7

5.4

–

*All grab and chip samples reported here were taken by CANEX personnel with all chip samples taken perpendicular to the strike of the structures sampled. Grab samples are selective in nature and are not necessarily representative of mineralization on the property

The Pit Zone contains a 150-metre-long by 40-metre wide open pit along with a northeast trending quartz vein with multiple historic workings along it that extends several hundred metres from the pit. Limited historical records indicate the pit was mined around 1981 by Houston Kingman Mining Company. Exposed in the pit is a sericite altered and quartz veined intrusive dike as well as quartz veining cutting and following foliation in the surrounding metamorphic rocks. At least 5 sub parallel mineralized quartz veins 0.5 to over 1 metre wide are exposed in the pit. Mineralized quartz veins contain copper oxide staining and locally minor amounts of chalcopyrite and galena. Current exposures indicate the quartz veined and altered zone is 30 metres wide or more. Fine visible gold within quartz was observed in 2 of the samples taken from the zone.

Dr. Shane Ebert, President of the Company stated, "Preliminary sampling from the Pit Zone is showing excellent potential for multiple zones of high-grade gold mineralization grading over 30 g/t gold associated with a wider mineralized halo as demonstrated by chip sampling which returned 2.3 g/t gold over 8 metres and only covered a portion of the potential width of the system. Mineralization is associated with elevated copper values and a wider zone of intensely altered and mineralized intrusive dikes than has been observed elsewhere on the property. These could be important clues to a district scale zonation that could help ongoing evaluation and targeting in the district. A field crew has just completed additional detailed mapping and sampling of the Pit Zone, which is a priority in our ongoing target evaluation program."

Exploration Update – A high-resolution airborne drone magnetic survey has recently been completed at Gold Range with final results expected near the end of the year. A CANEX field team has just completed a 10 day program of detailed geologic mapping and sampling on multiple new targets. Assay results from this program should be expected early in the new year. A soil sampling program consisting of over 400 samples over select targets will commence this week.

Quality Control – All samples were taken by CANEX representatives and shipped to American Assay Laboratories in Reno, Nevada (which is ISO/IEC 17025 accredited) for analyses. Gold was assayed using a 30g fire assay (method FA-PB30-ICP) with all gold samples greater than 10 g/t redone using a 30g fire assay method with a gravimetric finish (method GRAVAu30). Duplicates, blanks, and certified standards are analyzed with every sample batch and then checked to ensure proper quality assurance and quality control.

About the Gold Range Property – The Gold Range Property is located in Northern Arizona within an area that has seen historic lode and placer gold production but limited systematic modern lode gold exploration. Fieldwork by CANEX has identified numerous gold exploration targets on the property with grab samples from outcropping quartz veins returning multiple values in the 20 to 40 g/t gold range, and chip sampling returning values of 28.1 g/t gold over 1 metre and 8.47 g/t gold over 5.6 metres.

Dr. Shane Ebert P.Geo., is the Qualified Person for CANEX Metals and has approved the technical disclosure contained in this news release.

"Shane Ebert"

Shane Ebert, President/Director

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Except for the historical and present factual information contained herein, the matters set forth in this news release, including words such as "expects", "projects", "plans", "anticipates" and similar expressions, are forward-looking information that represents management of CANEX Metals Inc. internal projections, expectations or beliefs concerning, among other things, future operating results and various components thereof or the economic performance of CANEX. The projections, estimates and beliefs contained in such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause CANEX's actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. These risks and uncertainties include, among other things, those described in CANEX's filings with the Canadian securities authorities. Accordingly, holders of CANEX shares and potential investors are cautioned that events or circumstances could cause results to differ materially from those predicted. CANEX disclaims any responsibility to update these forward-looking statements.

For Further Information Contact:

Shane Ebert at 1.250.964.2699 or
Jean Pierre Jutras at 1.403.233.2636
Web: http://www.canexmetals.ca

SOURCE: CANEX Metals Inc.

ReleaseID: 570055

BUDA, TX / ACCESSWIRE / December 16, 2019 / Today Cipherloc Corporation (OTCQB:CLOK) ("CipherLoc"), a developer of quantum-secure encryption technology continues to refocus its internal structure on delivering solutions to customers across both public and commercial markets with the hiring of Ben Poernomo as Chief Marketing Officer and the promotion of Ron Coby to Vice President of Corporate Development.

Ben Poernomo joins CipherLoc from Symantec Corporation's National Security Group, after a previous career in military, government and commercial cybersecurity roles. Ben will be based in the Washington, D.C. area and will lead the go-to-market strategy for CipherLoc's quantum-secure encryption products and services.

Ron Coby has most recently served as CipherLoc's National Sales Director after consulting with the company over the past year. He joined the team after a previous career in capital markets. In his new role, Ron will report directly to the CEO with a focus on enterprise growth. His portfolio will include mergers and acquisitions, as well as joint ventures, partnerships and other strategic relationships.

"Ben and Ron are both stepping into significant new roles at an important time for our company. They are charged with taking CipherLoc's encryption technologies out of the laboratory and into the field for our government and commercial enterprise customers," said Andrew Borene, CEO of Cipherloc Corporation. "These hires are evidence of our simple and relentless focus on the commercialization of CipherLoc's most promising encryption solutions and associated services."

"CipherLoc's polymorphic encryption engine is unique among available technologies, and I look forward to working with Andrew and the rest of the team to bring that value to our customers in ways that meet their individual data security needs," said Ben Poernomo, new Chief Marketing Officer.

"After being involved with CipherLoc for over a year and developing strong relationships with partners across the government and commercial sectors, I look forward to the challenge of continuing to expand our current partnerships and identifying new areas for organic and strategic growth across the marketplace," said Ron Coby, new Vice President of Corporate Development.

Background – Ben Poernomo, Chief Marketing Officer

Ben Poernomo brings extensive cybersecurity experience in threat analysis and response, commercial channel development and government sales leadership. He was previously engaged in the National Security Group at Symantec, where he oversaw sales and engineering activity in the federal public sector, including threat intelligence. He was also Chief of Operations for IBM's X-Force Command CTOC, where he led immersive cyber incident simulations and responses for Global 2000 and larger enterprises. Additionally, he has led innovative technology development programs in various Department of Defense agencies while at Visionist, Inc and has experience in procurement for joint cyber capability programs of the US armed forces.His experience includes eight years of service in the U.S. Army's intelligence and cyber operations.

Background – Ron Coby, Vice President of Corporate Development

Ron Coby joined Cipherloc full-time in October 2019, after more than a year as a consultant helping the company strategically navigate its early growth. He has played a key role in the company's early partnership successes and continues to cultivate additional strategic partner relationships. He is a 30-year securities industry veteran with a diverse background, including stints as a stockbroker, investment banker, financial analyst, market strategist, venture capitalist and hedge fund manager.

About Cipherloc Corporation (OTCQB: CLOK)

Cipherloc Corporation is a provider of highly secure, quantum-safe data protection technology. Our highly innovative solutions are based on our patented Polymorphic Cipher Engine which is designed to add a layer of protection to existing products, services, or applications. We deliver solutions that are highly secure, synergistic, and scalable across a variety of applications and markets that demand mission critical encryption capabilities. In short, we keep information safe in today's highly dangerous world. For further information, please go to www.cipherloc.net.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set forth in the Company's SEC filings. These risks and uncertainties could cause the Company's actual results to differ materially from those indicated in the forward-looking statements.

Media Contact:

Loren Mahler
Dealy Mahler Strategies, LLC
703-201-1692
loren@dealymahlerstrategies.com

Investor Contact:
Matt Kreps
Darrow Associates Investor Relations
214-597-8200
mkreps@darrowir.com

SOURCE: Cipherloc Corporation

ReleaseID: 570053